Patent application number | Description | Published |
20080317761 | Peptide-Mediated Protein Transduction Into Cells of the Hematopoietic Lineage - A pharmaceutical composition comprises a therapeutic peptide or protein, a transport moiety capable of transporting said first peptide or protein into a hematopoietic cell differentiated from a common myeloid progenitor, and a linker between said first protein and said transport moiety, said linker susceptible to cleavage by an intracellular enzyme in the cell. A cell or collection of cells, e.g., platelets, containing such a composition is useful in methods for treating infection, inflammation, vascular injuries or any disorders involving or mediated by cells of the hematopoietic lineage. Methods of making such compostions are also disclosed. | 12-25-2008 |
20090130104 | FUSION PROTEINS FOR INHIBITION AND DISSOLUTION OF COAGULATION - Fusion proteins containing a ligand which specifically binds to a selected vascular bed linked to an anti-thrombotic molecule are provided. Also provided are methods for use of these fusion proteins to prevent coagulation, to dissolve blood clots and to protect against the risk of iatrogenic side effects including those arising from cancer therapy and specific vascular occluding agents. | 05-21-2009 |
20090264628 | CRYSTAL STRUCTURE OF HUMAN UROKINASE PLASMINOGEN ACTIVATOR AMINO TEMINAL FRAGMENT BOUND TO ITS RECEPTOR - Urokinase-type plasminogen activator (uPA) binds its cellular receptor (uPAR) with high affinity, thus localizing the generation of plasmin from plasminogen on the surface of a variety of cells. Disclosed herein is the structure of suPAR (uPAR | 10-22-2009 |
20100285015 | TARGETING RECOMBINANT THERAPEUTICS TO CIRCULATING RED BLOOD CELLS - Fusion proteins comprising a single chain antigen-binding domain (scFv) of a monoclonal antibody, linked to an anti-thrombotic agent, anti-inflammatory agent, or a pro-drug thereof are provided, where the polypeptide binds to a binding site (antigen) expressed on the surface of a red blood cell at a density greater than 5,000 copies per red blood cell. Pharmaceutical compositions comprising these fusion proteins, and methods of delivering an anti-thrombotic agent to the surface of a red blood cell via delivery of these fusion proteins, and methods of treating or preventing thrombosis, tissue ischemia, acute myocardial infarction (AMI), ischemic stroke, cerebrovascular disease, pulmonary embolism, or ischemic peripheral vascular disease via administration of the fusion proteins or compositions comprising same are also provided. | 11-11-2010 |
20110262466 | COMPOSITIONS CONTAINING THROMBOMODULIN DOMAINS AND USES THEREOF - Compositions are provided comprising a thrombomodulin domain linked to a targeting moiety that binds to a determinant on the surface of a target endothelial cell or red blood cell, wherein the thrombomodulin domain may be the extracellular domain, the N-terminal lectin-like domain, or an epidermal growth factor (EGF)-like domain. The targeting moiety may be a single chain antigen-binding domain (scFv), and the targeting moiety and thrombomodulin domain of the composition may be linked as a continuous polypeptide chain. Methods of delivery and use of a composition described herein are provided, as well as methods of treating or preventing thrombosis, inflammation, tissue ischemia, sepsis, acute lung injury (ALI), acute myocardial infarction (AMI), ischemic stroke, cerebrovascular disease, pulmonary embolism, or ischemic peripheral vascular disease is provided. | 10-27-2011 |
20130058929 | FUSION PROTEINS FOR INHIBITION AND DISSOLUTION OF COAGULATION OF THROMBI - Fusion proteins containing a ligand which specifically binds to a selected vascular bed linked to an anti-thrombotic molecule are provided. Also provided are methods for use of these fusion proteins to prevent coagulation, to dissolve blood clots and to protect against the risk of iatrogenic side effects including those arising from cancer therapy and specific vascular occluding agents. | 03-07-2013 |
20150037821 | METHODS OF IDENTIFYING HIT-ANTIBODIES AND PF4 ANTAGONISTS AND CELL LINES FOR USE THEREIN - Methods and cells or cell lines for identifying antibodies or fragments thereof that activate heparin-induced thrombocytopenia (HIT) are described. The methods comprise contacting a hematopoietic cell or cell line that comprises, in operative association, the platelet receptor FcyRIIA under the control of a suitable promoter, and a reporter construct comprising a reporter gene under the control of a promoter and transcription factor, which transcription factor is regulated downstream of the signaling cascade of activated FcyRIIA, with a test sample from a mammalian subject; a platelet factor 4 (PF4), a wild-type or variant of PF4 or a fragment thereof; and heparin; and detecting or measuring the level of reporter gene expression. | 02-05-2015 |
20150132778 | METHODS AND KITS FOR DIAGNOSING HEPARIN-INDUCED THROMBOCYTOPENIA - Provided herein are methods for diagnosing heparin-induced thrombocytopenia (HIT) in a subject. The methods comprise (a) contacting a PF4-heparin complex with a biological sample from the subject; (b) contacting the composition of part (a) with an HIT-like antibody; and (c) measuring the amount of bound HIT-like antibody. In one embodiment, a significant decrease in the amount of bound HIT-like antibody in the composition of part (b) as compared to a control level is indicative of a diagnosis of HIT in the subject. Also provided are assay kits for performing the methods of the invention. | 05-14-2015 |